Objective: Generation of human livers in pigs might improve the serious shortage of grafts for human liver transplantation, and enable liver transplantation without the need for deceased or living donors. We developed a chimeric liver (CL) by repopulation of rat hepatocytes in a mouse and successfully transplanted it into a rat recipient with vessel reconstruction. This study was designed to investigate the feasibility of CL for supporting the recipient after auxiliary liver grafting. Methods: Hepatocytes from luciferase transgenic or luciferase/LacZ doubletransgenic rats were transplanted into 20-to 30-day-old urokinase-type plasminogen activator/severe-combined immunodeficiency (uPA/SCID) mice (n = 40) to create CLs with rat-origin hepatocytes. After replacement of mouse hepatocytes with those from rats, the CLs were transplanted into wild-type Lewis (n = 30) and analbuminemia (n = 10) rats, followed by immunosuppression using tacrolimus (TAC) with/without cyclophosphamide (CPA) or no immunosuppression. Organ viability was traced by in vivo bioimaging and Doppler ultrasonography in the recipient rats for 4 to 6 months. Rat albumin production was also evaluated in the analbuminemia rats for 4 months. In addition, histological analyses including Ki67 proliferation staining were performed in some recipients. Results: Both immunosuppressive protocols significantly improved graft survival and histological rejection of CLs as compared to the nonimmunosuppressed group. Although rat albumin production was maintained in the recipients for 4 months after transplantation, ultrasonography revealed patent circulation in the grafts for 6 months. Ki67 staining analysis also revealed the regenerative potential of CLs after a hepatectomy of the host native liver, whereas immune reactions still remained in the mouse-origin structures. Conclusions: This is the first report showing that engineered CLs have potential as alternative grafts to replace the use of grafts from human donors.
L
iver transplantation is currently regarded as the most effective treatment for end-stage liver diseases. Because the worldwide graft shortage remains unresolved, 1,2 engineered organs are anticipated as alternative grafts to fill the scarcity and ultimately replace those from deceased and living donors. Although regenerative technology has already developed various kinds of regenerative cells and tissues, 3, 4 they are still insufficient to cure patients with end-stage liver diseases because of the absence of complicated functions and limited volume. Therefore, a regenerative liver graft for use as an "organ" is required. To achieve an appropriate 3-dimensional structure and differentiation to specific tissues in a single organ, application of native organs as scaffolds has been reported as a possible solution. [5] [6] [7] Recent advances in genetic manipulation of animals such as pigs have produced transgenic animals with a lower risk of xenorejection. 8, 9 Thus, using their native organogenetic potentials, development of engineered liver "organs" is expected. 10 In such a protocol, human hepatocytes are transplanted to a transgenic pig to replace its native hepatocytes, resulting in development of a chimeric liver (CL) with human parenchyma and swine nonparenchymal components, including vessels, bile ducts, and other connecting tissues. However, it is unclear whether such engineered CLs can be transplanted into recipients, or whether they can maintain their organ structures and functions after transplantation. In this study, we developed a rodent model of chimeric liver transplantation to investigate its feasibility (Fig. 1A) . We used mice and rats as substitutes for transgenic pigs and humans, respectively, and created CLs in transgenic mice using hepatocytes derived from transgenic rats. After chimeric liver transplantation into rat recipients with vessel reconstruction, we examined the long-term viability and functions of the transplanted CL grafts.
MATERIALS AND METHODS Animals
All mice and rats were housed in a temperaturecontrolled environment under a 12-hour light-dark cycle with free access to water and standard rodent chow diet. Male and female albumin enhancer-/promoter-driven urokinase-type plasminogen activator/severe-combined immunodeficiency (uPA/SCID) mice (Phoenixbio Co, Ltd, Japan) (n = 40), which express and accumulate urokinase-type plasminogen specifically in native hepatocytes, resulting in liver disease, 11, 12 were used as the scaffolds for CL regeneration. Male luciferase transgenic Lewis (Luc-LEW) (MHC haplotype; RT1 l ) 13 (n = 2), and female luciferase and LacZ double-transgenic Lewis (Luc/LacZ-LEW) (RT1 l ) rats 14 (n = 1) were used as hepatocyte donors. Male wild-LEW rats (RT1 l ) (Charles River Japan, Japan) (n = 30) and male Nagase analbuminemia rats (RT1 a ) 15 (Japan SLC, Japan) (n = 10) were used as the recipients of chimeric liver transplantation. All experiments in this study were performed in accordance with the Jichi Medical University Guide for Laboratory Animals after approval by the ethics committee of PhoenixBio Co, Ltd. perfusion method. 16 Collagenase (75 mg/body) (COLLAGENASE S-1; Nitta-gelatin, Japan) was perfused through the portal vein, then 5.0 × 10 5 hepatocytes were transplanted into 20-to 30-day-old uPA/SCID mice, as previously reported. 12 These mice were kept for 3 months to obtain CLs with satisfactory size (mean ± SEM, 1.69 ± 0.04 g) and chimerism.
Harvesting of CLs
The CLs were harvested from uPA/SCID mice along with the hepatic artery with the aortic cuff and infrahepatic inferior vena cava. The portal vein trunk, common bile duct, and suprahepatic inferior vena cava were ligated. After systemic injection of 300 U of heparin sodium (Novo-Heparin; Mochida, Japan), the graft was harvested and cryo-preserved in 0.9% saline. A 10-mm plastic tube (22G SurfloR, IV catheter; Terumo, Japan) was inserted into the gallbladder, and a plastic cuff (18G SurfloR) was installed onto the end of the infrahepatic inferior vena cava.
Auxiliary Liver Transplantation of CLs
The CLs were engrafted in an auxiliary manner with vessel reconstruction using a cuff technique, as we previously reported. 17 In brief, after a simple left nephrectomy, a plastic cuff (22G SurfloR) was installed on the end of the recipient left renal artery. The graft hepatic artery and infrahepatic inferior vena cava were anastomosed to the recipient left renal artery and vein, respectively (see Video and Figure, Supplemental Digital Contents 1 and 2, demonstrating reperfusion of graft, available at http://links.lww.com/SLA/A254 and http://links.lww.com/SLA/A256, respectively). The graft gallbladder was connected to the recipient jejunum (Fig. 1B) and the recipient liver was left intact. There were no significant differences regarding any of the parameters for the animals and surgical procedures (data not shown). Recipient rats that died within 24 hours after chimeric liver transplantation or showed no luminescent signals on day 1 were excluded from postoperative analyses.
PostTransplant Treatment
Solid immunosuppressive protocols with tacrolimus (TAC) for T cell-mediated rejection and cyclophosphamide (CPA) for antibodymediated rejection were used. The LEW rat recipients were treated with one of the following protocols: daily tacrolimus [TAC (+)CPA (−)] (n = 15), daily tacrolimus and cyclophosphamide pretreatment [TAC (+)CPA(+)] (n = 6), or no immunosuppression [TAC(−)CPA(−)] (n = 6). In the TAC(+)CPA(−) and TAC(+)CPA(+) groups, tacrolimus (Prograf; Astellas, Japan) was injected intramuscularly into the recipient rats at a dose of 0.64 mg/kg before and every day after transplantation. In TAC (+)CPA(+), candidate recipient rats were prepared with an intraperitoneal injection of cyclophosphamide (Endoxan, Shionogi, Japan) at a dose of 60 mg/kg 10 days before transplantation (dose of cyclophosphamide modified from previous report 18 ). For Nagase analbuminemia rat recipients (n = 8), tacrolimus was given every day intramuscularly at a dose of 0.32 mg/kg. The recipient rats were observed daily and those in very poor condition were euthanized.
Evaluation of Luminescence From CLs
In vivo luciferase imaging of CLs was performed in both uPA/SCID mice for 3 months after hepatocyte transplantation and recipient rats throughout their survival after chimeric liver transplantation using a noninvasive bioimaging system (IVIS, Xenogen, CA), and the images were analyzed using a software package (Igor; WaveMetrics, OR, and IVIS Living Image; Xenogen). Before imaging, D-luciferin (potassium salt; Biosynth, Switzerland) (30 mg/kg) was injected into the peritoneal cavity of uPA/SCID mice or the penile vein of recipient rats. Signal intensity was quantified as photon flux in units of photons (s/cm 2 /steradian) in the region of interest.
ELISA for Serum Rat Albumin Levels
Blood samples were obtained from uPA/SCID mice for 3 months after hepatocyte transplantation and Nagase analbuminemia rat recipients for 4 months after chimeric liver transplantation. To examine hepatic functions specific to CLs in our model with an intact recipient liver, we measured serum rat albumin using a Rat Albumin ELISA KIT (AKRAL-120, Shibayagi, Japan).
Histological Analyses
Tissue samples were fixed in 10% formalin for hematoxylineosin staining, and 10-μm thick sections were used. For X-gal and immunohistochemical staining, 4%-paraformaldehyde-fixed frozen samples were sliced into 4-μm thick sections. X-gal analyses were performed as previously reported.
14 Immunohistochemical analyses of the CL grafts were performed before and 2 days after the host left lobectomy with anti-Ki67 rabbit polyclonal antibody (RB-1510-P, Thermo Fisher Scientific, CA). Fifteen random views of each sample were obtained and Ki67-positive hepatocytes were separately counted in areas (mm 2 ) with viable hepatocytes using image software (Scion Image; Scion, MD).
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Ultrasonographic Analyses
Blood flow velocities were measured using an ultrasound system (Prosound SSD-α5; ALOKA, Japan). Velocity was quantified in unit of cm/second.
Statistical Analyses
We performed statistical analyses using StatView5.0 (SAS, NC). We used the analysis of variance test and Holm-Sidak as a post hoc test. Data are presented as the mean ± SEM, with values of P < 0.05 considered to be statistically significant.
RESULTS

Development of CL Grafts in Mice
On the basis of the repopulation of transplanted rat hepatocytes in uPA/SCID mice, the spreading of positive areas was observed using in vivo bioluminescent imaging (Fig. 2A) . Luminescent fluxes increased rapidly and reached a plateau for approximately 3 months after hepatocyte transplantation (Fig. 2B) . Moreover, serum rat albumin concentration on day 30 was significantly higher than that on day 5, then remained until day 85 (Fig. 2C) . Luminescent fluxes and albumin concentrations were strongly correlated (Spearman correlation coefficient r = 0.86, P < 0.0001), suggesting that luminescence reflected CL function. The appearance was that of a normal mouse liver (Fig. 2D) . Although hematoxylin-eosin staining showed normal histological structures, X-gal staining revealed that the mouse hepatic parenchyma was nearly entirely replaced by LacZ-positive rat hepatocytes, except for the other hepatic components, such as the vessels and bile ducts in Glisson capsules (Fig. 2E) .
Graft Viability After Auxiliary Transplantation
In the TAC(−)CPA(−) group, luminescence vanished rapidly until day 5 after Chimeric liver transplantation, whereas it was stably maintained for 4 weeks in both TAC(+)CPA(−) and TAC(+)CPA (+). There was no significant difference between those 2 groups (Fig. 3A) .
Histological Analyses of Transplanted CL Grafts
Hematoxylin-eosin staining showed massive necrosis and destruction of the arrangement of the hepatic lobules in TAC(−)CPA(−) on day 5 (Fig. 3B) . In contrast, TAC(+)CPA(−) on day 7 showed maintenance of those, even with massive cellular infiltration from the Glisson capsules to the central areas (Fig. 3C) . Furthermore, in TAC(+)CPA(+), the hepatic structures were maintained with fewer rejection changes (Fig. 3D) . Even on day 14, the TAC(+)CPA(+) protocol protected the CL from severe xenobiotic rejection, with only moderate cellular infiltration in the Glisson capsules (Fig. 3E) .
Long-Term Patency of Reconstructed Vessel Circulations
Doppler ultrasonography showed the flow patterns of the arterial inflow and venous outflow in the transplanted CLs on days 14 and 188 in the TAC(+)CPA(−) group. Peak velocities on day 14 were 34.2 (artery) and 9.9 (vein) cm/s, whereas those on day 188 were 12. 
Long-Term Maintenance of Secretion of Rat Albumin in Nagase Analbuminemia Rats
Although serum rat albumin concentrations in Nagase analbuminemia rat recipients were undetectable before Chimeric liver transplantation, the transplanted CLs produced albumin on day 5 and then maintained production for 4 months, with maintenance of luminescence under the TAC(+)CPA(−) protocol (Fig. 4A) . FIGURE 2. Development of CL grafts in uPA/SCID mice. A, Spread of luminescence-positive area. B, Luminescence after hepatocyte transplantation in 3 independent series. n as indicated; values are shown as the mean ± SEM; n.s., no significant difference on day 85. C, Production of rat albumin by transplanted rat hepatocytes in mice (n = 12).
Self-Regenerative Capacity of Transplanted CL
Ki67 immunohistochemical analyses revealed that Ki67-positive cells were significantly increased in the CLs and in the remnant native livers at 2 days after the left lobectomy in the recipients, as compared with those sampled before the hepatectomy (Fig. 4B-F) , suggesting the proliferative potential of the transplanted CLs.
DISCUSSION
The chronic shortage of liver grafts has led to extended criteria for grafts from both deceased 19, 20 and living donors, 21 along with ethical issues related to organ trafficking and transplant tourism. 22 Although alternative therapies, such as hepatocyte transplantation, 23 transplantation from non-heart beating donors, 24 bioartificial liver, 25 and xenotransplantation, 26, 27 have been intensively investigated to address this situation, none has been found practical because of low stability, low availability, and high antigenicity.
Regenerative approaches have recently been applied to develop engineered organs by focusing on native organs as scaffolds. An approach using a decellularized organ matrix enabled regeneration of syngeneic cells in an animal model, 5, 6 though cell repopulation efficiency was still low in ex vivo conditions. Another study injected blastocysts with xenogeneic pluripotent stem cells to produce a chimeric pancreas in a rodent model. 7 However, ubiquitous chimerism in scaffold animals has led to ethical concerns about the formation of chimeric brains and genitalia. Thus, effective and organspecific engineering is required.
We have developed a strategy to create engineered chimeric "organ" livers with autologous or allogeneic human hepatocytes and other nonparenchymal components from xenogeneic scaffolds in transgenic pigs. This method enables utilization of patent hepatocytes and allogeneic donor cells, and the organogenetic potential in living animals contributes to rapid and timely production of CLs. Moreover, pretreatment with drugs or gene induction in the donor animal may be useful before transplantation.
In this study, we successfully created a rodent model to generate organ-specific engineered CLs, followed by their transplantation. CLs were created in uPA/SCID mice, whose native hepatocytes are injured through accumulation of urokinase-type plasminogen and provide a favorable niche for effective repopulation of transplanted hepatocytes from rats 28 and humans, 11 with a replacement rate greater than 90%. 12 Using hepatocytes derived from transgenic rats with
luciferase or LacZ genes, we found that transplanted hepatocytes in mice spread promptly and stably maintained their viability. Rat albumin production and histological analyses also indicated stable functions and structures of the CLs. These results demonstrated the advantages of CLs with effective productivity and maintenance. Because the CLs were one-eighth smaller than the rat native livers, we transplanted in an auxiliary manner without a hepatectomy or removal of the recipient liver. In addition, we removed the recipient's left kidney to utilize the left renal artery and vein as afferent and efferent vessels, respectively. We considered that a left nephrectomy would not have a large impact on our aim to investigate chimeric liver transplantation feasibility, whereas it might have an influence on recipient's survival. Moreover, though clinical liver transplantation and most rat liver transplantation models reconstruct portal vein circulation, we left it unanastomosed, as we previously reported in a rat auxiliary liver transplantation model, 17 in which the transplanted livers maintained their histological structure.
This analysis revealed severe rejection toward xenogeneic components, resulting in disappearance of luminescence in CLs without immunosuppression. Because humoral rejection was suspected in xenorejection toward the vascular endothelium, 29 we used cyclophosphamide to suppress antibody production in addition to tacrolimus. 18 Our results showed improvement in graft survival in the immunosuppressed groups. TAC(+)CPA(+) showed higher luminescence as compared with TAC(+)CPA(−), though there was no statistical difference between them. On the other hand, histological results showed the superiority of TAC(+)CPA(+). We speculated that these findings indicated antibody-mediated rejection even in Chimeric liver transplantation and that appropriate combination therapies might improve graft survival. Although we previously hypothesized that syngeneic parenchyma might function to protect against rejection toward xenocomponents, 30 the reaction to mouse-origin tissues remained without obvious evidence of attenuation. Further studies to investigate the effects of hepatocytes and specific targets of rejection are required, including those that focus on other aspects such as genetic expressions. 31 In clinical liver transplantation, thrombotic events can result in graft failure. 32 Ultrasonography showed arterial and venous flow in transplanted CLs even after 6 months, which indicated patency of the anastomosed vessels. We also investigated rat albumin in Nagase analbuminemia rat recipients and demonstrated stable production for a long period. Although the liver possesses a variety of functions and markers, 3, 6 albumin analysis showed functions specific to transplanted CLs in Nagase analbuminemia rats with intact livers, which functioned normally except for albumin production. We regarded this result to be preferable in regard to our aim to investigate the feasibility of Chimeric liver transplantation to show those functions in vivo. Interestingly, we found stable luminescence in transplanted CLs of Nagase analbuminemia rat recipients whose hepatocytes were allogeneic to those of other recipients (RT1 l vs RT1 a ), suggesting the possibility of a hepatocyte bank for use in producing CLs in clinical settings.
Ki67 analyses showed that hepatocytes in the transplanted CLs maintained proliferation potential. Patients with end-stage liver disease are thought to manifest increasing serum hepatotropic growth signals, such as hepatocyte growth factor. 33 It is expected that CLs will have the potential to respond to such signals to maintain and improve viability after transplantation.
Judging from recent technological achievements in transgenic animals, and ethical issues related to primate usage and practical issues of availability and body size, transgenic pigs represent a major candidate for scaffold animals. Although transgenic pigs such as alpha-1,3-galactosyltransferase gene knockout and human decay accelerating factor transgenic pigs show reduced immunological responses toward the host, complete rejection suppression remains difficult and development of appropriate immunosuppressive protocols is important. Moreover, replacement of nonhepatocyte components, especially vascular endothelium, in the CLs of scaffold pigs or development of humanized pigs is expected. However, utilization of xenogeneic porcine scaffolds raise concerns about xenozoonosis such as porcine endogenous retrovirus, 34, 35 though the practical possibility of transmission remains uncertain and some reports have shown results without obvious infection. 36 Nevertheless, cautious and longer investigations are indispensable to secure patient safety.
Although further studies that compare conventional liver transplantation models with this model and larger animal models are needed, the realization of this bioengineering strategy with cell sources and transgenic animals might ultimately lead to replacement of human grafts and achievement of liver transplantation without human donors. These results should provide an important contribution toward scaffold-focused engineering of livers and engineered organ transplantation.
CONCLUSIONS
Engineered CLs were successfully transplanted and showed maintenance of function and structure for a long period. Our results suggest that such CLs have potential to be utilized as alternative grafts.
